| Literature DB >> 1103113 |
R Sturrock, A Isaacs, F D Hart.
Abstract
A double-blind cross-over trial of feprazone 450 mg daily and indomethacin 75 mg daily was carried out in fourteen patients with rheumatoid arthritis. The analgesic and anti-inflammatory activity was indistinguishable from that of indomethacin under the conditions of the trial. Seven patients expressed a preference for feprazone and four for indomethacin. Feprazone appeared to be well tolerated and free from serious side-effects. These results suggest that feprazone will be a useful drug in the management of rheumatoid arthritis.Entities:
Mesh：
Substances：
Year: 1975 PMID： 1103113
Source DB: PubMed Journal: Practitioner ISSN： 0032-6518